Saturday, October 24

Boehringer Ingelheim designs a new Arabic website to help regional Patients having Idiopathic Pulmonary Fibrosis; a short review

This year September 14-22 has been considered as Idiopathic Pulmonary Fibrosis Awareness Week. To make this week fruitful, Boehringer Ingelheim, one of the greatest pharma giants has launched a brand new Arabic website for the patients having Idiopathic Pulmonary Fibrosis in the region. The online program has been arranged to deliver patients, health workers an authentic source of knowledge on the illness, risk factors, signs and symptoms, and medicaments. The Arabic language is also included so that it can understand by every local people easily. Besides these, frequently asked proposals and a glossary with numbers of medical terms has been included to help to understand the condition.

Approximately 60 million people are having this kind of respiratory problems in the Middle East region solely. Generally, Idiopathic Pulmonary disorders occur when lung tissues get damaged and the development of scar tissue that causes difficulty in breathing.

The high rate of smoking, obesity, and severe weather condition in the region can be considered as the major cause of the ailment. Genetics also play a crucial role in IPF. It can be that 20% of IPF patients have a family history with similar lung disease.

There are several symptoms such as dry cough, chest pain, shortness of breath, and fatigue among others. Concerning the risk factors, most of the diagnosed patients are above 50 and 75% of those are male.


A year ago Boehringer Ingelheim launched an Arabic website in awareness of the rising need for more information about IPF in the word following the primary growth of the English website. “Living with Pulmonary Fibrosis,” the website includes various features to support patients, families, and healthcare specialists across the Middle East. All information on the website can be obtained in connection with proposed therapies and checkups and includes facts and statistics about the disease, its symptoms and risk factors, advice for patients, and leadership for patient families and medical personnel.


“As an uncommon respiratory disease, IPF can be testing to diagnose and we at Boehringer Ingelheim are dedicated to supporting patients living with rare diseases and assisting them to live their lives to the fullest,” noted Dr. Mohamed Meshref, Regional Medical and Regulatory Director at Boehringer Ingelheim Middle East, Turkey, and Africa.


Leave a Reply

Your email address will not be published. Required fields are marked *